Bosch Healthcare Solutions

What Bosch Healthcare Solutions does

Bosch Healthcare Solutions GmbH is a wholly-owned subsidiary of Robert Bosch GmbH, founded in 2015 and headquartered in Waiblingen, Germany, with 51-100 employees (120+ as of 2019). The company develops and commercializes two principal product lines: Vivalytic, an open, universal molecular diagnostics platform that performs fully automated PCR-based testing (endpoint-PCR, quantitative real-time PCR, melting curve analysis, and microarray) at the point of care via single-use cartridges containing all required reagents and supporting singleplex through high-multiplex panels; and Vivatmo, a breath gas analysis system for fractional exhaled nitric oxide (FeNO) measurement, comprising Vivatmo pro for clinical settings and Vivatmo me, the world's first home-use FeNO device. Core technical differentiators include proprietary BioMEMS silicon-chip technology enabling 250+ genetic markers in under 15 minutes, and intelligent programmable microfluidics that allow parallel analysis of viruses, bacteria, and fungi on the same cartridge without refrigeration.

The business model combines hardware revenue (Vivalytic Analyzer, Vivatmo devices), high-margin recurring consumables (single-use test cartridges and disposable mouthpieces), and software/cloud services via the Vivasuite IoMT platform. Go-to-market is hybrid: direct enterprise field sales to hospitals, clinics, and medical practices, complemented by global distribution through strategic co-development partners Randox Laboratories and R-Biopharm AG (each committing approximately €150 million), a technology partnership with BioGX for US-validated test content, and direct-to-patient sales of Vivatmo me. Reimbursement is enabled through an innovation partnership with the German Private Health Insurance Association (PKV), covering approximately 8.7 million private insureds for Vivalytic PCR tests.

Target customer segments include healthcare providers performing point-of-care molecular diagnostics (primary), clinical laboratories seeking high-multiplex PCR capability, and asthma patients requiring home-based FeNO monitoring. The company leverages Bosch Group competencies in sensors, miniaturization, manufacturing, and software, while operating with its own management team under co-Managing Directors Marc Meier and Alexander Fritsch. The company has set a 2030 revenue target in the mid three-digit million Euro range, driven by Vivalytic partner-channel expansion, test menu growth (recent additions include Bacterial Meningitis, C. auris, Bordetella, MRSA, STI panels, and SARS-CoV-2 pooling), and US market entry for Vivatmo initiated in 2024.

Name

Bosch Healthcare Solutions

Legal name

Bosch Healthcare Solutions GmbH

Website

https://bosch-healthcare.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics and Point-of-Care Testing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

akta.pro secondary industries

Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Molecular diagnostics platform
• Point-of-care PCR testing
• Breath analysis devices
• FeNO measurement systems
• In-vitro diagnostics cartridges

Headquarters

HQ city

Waiblingen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Vivalytic Analyzer Hardware Sales: Sale of Vivalytic molecular diagnostics analyzer - a fully automated platform device approximately the size of a computer tower. No additional peripheral devices required.
2. Test Cartridge Sales: Single-use test cartridges containing all required reagents. Available in versions with 6 or 9 liquid reagents. Compatible with all Vivalytic Analyzers. Tests include SARS-CoV-2, respiratory infections, STI panels, MRSA, Candida auris, bacterial meningitis, Bordetella, and more.
3. Vivatmo Device Sales: Sale of Vivatmo breath gas analysis devices - Vivatmo pro for clinical settings and Vivatmo me for home use. Includes disposable mouthpieces.
4. Software Services: Vivatmo app for smartphone data sync and management. Vivasuite cloud platform for medical device management and updates.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Bosch Healthcare Solutions develops and sells the Vivalytic universal molecular diagnostics platform (an automated PCR-based analyzer with single-use test cartridges for point-of-care infectious disease detection) and the Vivatmo breath analysis system (Vivatmo pro for clinics and Vivatmo me for home use) for fractional exhaled nitric oxide (FeNO) measurement in asthma patients. The company also provides Vivasuite cloud-based device management platform and Bosch Origify product authentication technology for medical instruments.

Product overview

Bosch Healthcare Solutions offers a portfolio centered on two main product lines: Vivalytic (an open, universal molecular diagnostics platform for PCR-based testing at the point of care) and Vivatmo (a breath analysis system for FeNO measurement in asthma). Vivalytic consists of the Vivalytic Analyzer hardware and compatible single-use cartridges, supporting multiple PCR methodologies and partnering with test providers like Randox, R-Biopharm, and BioGX for diverse test panels. Vivatmo comprises Vivatmo pro (for clinical use) and Vivatmo me (the world's first home FeNO device), both supported by the Vivatmo app for data management. Supporting infrastructure includes Vivasuite (cloud-based device management platform), Software Engineering Services (custom medical software), and Bosch Origify (product authentication technology).

Differentiator

Problem solved

Functional benefit

Brands

• Vivalytic: Universal, open platform for molecular laboratory diagnostics with automated PCR testing at point of care
• Vivatmo
• Vivasuite
• Bosch Origify

Products and services

• Vivalytic Molecular Diagnostics Platform Universal open platform for molecular laboratory diagnostics that performs fully automated PCR-based testing using single-use cartridges containing all necessary reagents. Supports singleplex through high-multiplex testing. Designed for healthcare providers performing point-of-care testing for infectious diseases including SARS-CoV-2, respiratory infections, STIs, MRSA, Candida auris, bacterial meningitis, and Bordetella.
• Vivalytic Test Cartridges Single-use test cartridges for the Vivalytic Analyzer containing all required reagents, including specific tests for SARS-CoV-2 (single and pooling), respiratory infections, STI panels, MRSA, Candida auris, bacterial meningitis, and Bordetella. Cartridges do not require refrigeration and provide results in 30 minutes to under 2.5 hours.
• Vivatmo pro FeNO (fractional exhaled nitric oxide) breath analysis device for physician practices and clinics measuring airway inflammation in asthma patients. Maintenance-free with no calibration required. Generation 2.0 features 6-second mode for children aged 7-11 and faster repeat measurement readiness.
• Vivatmo me World's first FeNO breath analysis device for patient home use, enabling regular monitoring of airway inflammation in allergic asthma. Measures exhaled nitric oxide and syncs data via Bluetooth to smartphone app for tracking and physician sharing.
• Vivasuite Cloud-based platform for medical device management and a key component of the Internet of Medical Things (IoMT). Ensures optimal system availability through efficient update and device management, serving as the basis for customer-specific cloud solutions for Vivalytic and Vivatmo products.
• Bosch Origify Fingerprint technology that uses only the natural surface for product verification. Completely marker-free solution capable of capturing small instruments that are particularly difficult to mark. Includes app and digital management solution supporting product authentication, sales control, and lifecycle management.
• Healthcare Software Engineering Services Customized software solutions for medical technology offered by Bosch Healthcare Solutions and Bosch Global Software Technologies (BGSW), covering cloud, IoMT, AI, and data science technologies according to highest information security and data protection standards.

Quantifiable outcome

• 98% sensitivity, 100% specificity for SARS-CoV-2 rapid test
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, primary and supporting.

• R-Biopharm AGcoreStrategic or Co-development PartnerTen-year strategic development and distribution partnership investing 150 million Euro to develop new IVD tests for Vivalytic platform. Focus on PCR tests for multi-resistant gramnegative bacteria (MRGN) and tuberculosis. R-Biopharm brings expertise in clinical and food diagnostics plus established global distribution channels.
• Randox Laboratories Ltd.coreStrategic or Co-development PartnerStrategic partnership with Northern Irish medical technology company. Combined investment of approximately 150 million Euro. First partnership announced for Vivalytic BioMEMS technology. Goal to develop IVD high-multiplex sepsis test using novel BioMEMS technology.
• BioGX Inc.primaryTechnology or IntegrationUS company providing innovative reagent components for DNA/RNA-based tests. Partnership expands Vivalytic test portfolio with molecular tests at point-of-care. BioGX has over ten years of market experience in the USA with applications in water quality monitoring, NASA space research, and clinical laboratories.
• Verband der Privaten Krankenversicherung (PKV)primaryGTM or Marketing PartnerInnovation partnership enabling private physicians to bill for Vivalytic PCR tests. Covers tests for respiratory infections and ten STI pathogens. Benefits approximately 8.7 million private insureds in Germany.
• Robert Bosch KrankenhaussupportingStrategic or Co-development PartnerRenowned hospital partner for research, development, and testing of innovative health solutions.
• Bosch ForschungsupportingTechnology or IntegrationTechnology center providing access to current and future Bosch product portfolio know-how.
• Bosch BKKsupportingStrategic or Co-development PartnerHealth insurance with healthcare expertise enables validation of innovative business ideas.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Qiagen: Qiagen's QIAstat-Dx is a cartridge-based real-time PCR platform for syndromic respiratory, GI and meningitis testing at the point of care, directly overlapping with Vivalytic's respiratory, meningitis and STI test menu and open-platform go-to-market.
• Abbott: Abbott's ID NOW is a rapid molecular point-of-care platform and m-PIMA addresses HIV and molecular testing — Abbott competes with Vivalytic in rapid POC PCR while also serving broader diagnostics customers overlapping with Bosch's hospital-segment push.
• Circassia: Circassia's NIOX Vero is the market-leading clinical FeNO analyser used by pulmonologists and allergists worldwide, the dominant installed-base competitor against which Vivatmo pro must differentiate on usability and (via Vivatmo me) home use.
• Cepheid: Cepheid's GeneXpert system is the dominant cartridge-based PCR point-of-care platform with an extensive menu (including respiratory pathogens, MRSA, STI), making it Bosch Vivalytic's most direct global competitor in decentralized molecular diagnostics.
• bioMérieux: bioMérieux's BioFire FilmArray is a leading multiplex syndromic molecular POC platform for respiratory, bloodstream, GI and meningitis panels, the closest functional analogue to Vivalytic's high-multiplex PCR cartridge approach.
• Eco Medics: Eco Medics manufactures clinical FeNO and pulmonary function measurement devices used in allergy and pulmonology practices across Europe, a specialist competitor overlapping with Vivatmo pro's clinical customer base.
• Bedfont Scientific: Bedfont's NObreath and NObreath Flo devices are well-established clinical FeNO measurement instruments for asthma diagnosis and management, making them the closest direct competitor to Bosch's Vivatmo pro in physician offices and clinics.

Broad incumbents

• Hologic: Hologic's Panther Fusion and Aptima systems run molecular diagnostic assays including respiratory and STI panels at near-POC and central-lab settings — a broader diagnostics incumbent whose molecular menu overlaps Vivalytic's growing cartridge franchise.
• QuidelOrtho: QuidelOrtho (formed via Quidel–Ortho merger) operates Sofia and Savanna rapid and molecular diagnostic platforms spanning respiratory, infectious disease and women's health — a broader POC and central-lab incumbent with overlapping customers to Bosch Healthcare Solutions.
• Roche: Roche's cobas Liat system is a direct competitor in rapid POC PCR, and Roche Diagnostics' much larger portfolio (central-lab, sequencing, diabetes care) frames Roche as a broader incumbent against which Vivalytic must position.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@boschhealthcaresolutions
• Facebookfacebook.com/BoschVivatmoDeutschland
• LinkedInlinkedin.com/company/bosch-healthcare-solutions
• Instagraminstagram.com/bosch_vivatmo

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bosch Healthcare Solutions